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The present work describes the first quantitative molecular prediction using laser-induced molecular
bands along with chemometrics. In addition, this spectroscopic procedure has demonstrated the first
complete quantitative analysis utilizing traditionally insensitive elements for pharmaceutical
formulations. Atomic LIBS requires certain sensitive elements, such as Cl, F, Br, S and P, in order to
quantitate a specific organic compound in a complex matrix. Molecular LIBS has been demonstrated
to be the first successful approach using atomic spectroscopy to evaluate a complex organic matrix.
This procedure is also the first quantitative analysis using laser-induced molecular bands and
chemometrics. We have successfully applied chemometrics to predict the formulation excipients and
active pharmaceutical ingredient (API) in a complex pharmaceutical formulation. Using such an
approach, we demonstrate that the accuracy for the API and a formulation lubricant, magnesium
stearate, have less than 4% relative bias. The other formulation excipients such as Avicel and lactose
have been accurately predicted to have less than a 15% relative bias. Molecular LIBS and chemometrics
have provided a novel approach for the quantitative analysis of several molecules that was not
technically possible with the traditional atomic LIBS procedure, that required sensitive elements to be
present in both API and formulation excipients.
Introduction
The use of laser-induced breakdown spectroscopy (LIBS) for
qualitative analysis of organic material is currently a subject of
great interest in the LIBS community. However, the quantitative
analysis of organic compounds has not been reported yet using
LIBS spectral data and chemometrics. The combination of
chemometrics and LIBS has shown promising results for rapid
at-line multielemental quantitative analysis of aluminium alloys
using abundant certified reference materials.1 There have been
a number of wide ranging qualitative applications of LIBS for
organic compounds which include polymers,2,3 inks,4 hydrocar-
bons5 and coral beads.6 The topic that receives the most
attention is the use of LIBS for standoff analysis of explosive
residues and biological material for homeland security
applications.7–22 Many approaches have been proposed for
qualitative analysis of explosive residues.7–12,19,20,22 In particular,
the use of atomic ratio of neutral lines of nitrogen, oxygen and
carbon10–14,19,20,22 have been used for the differentiation of explo-
sives residues. However, these approaches have been hindered by
the atmospheric gases which are composed mainly of nitrogen,
and oxygen elements commonly found in non-metallic organic
materials. This has been a challenging technical problem for
standoff detection of organic material in air. To overcome these
issues, some researchers have proposed to include emission bands
of CN and C2 to the atomic ratio criterion for discrimination of
explosive residue spectra under atmospheric conditions.10–14
These approaches, along with the use of clustering
techniques16–20,22 and spectral database searches,10–12 have been
evaluated and suggest promise. Recently, Schade and Bohling
have proposed following the temporal emission decay of molec-
ular bands of CN along with an artificial neural network
approach to differentiate different explosive residues.7,8 The
multiplicity of research approaches and multivariate analysis
techniques show the fundamental interest in utilizing LIBS as
an analytical technique for the standoff detection of organic
compounds.
In the pharmaceutical arena, the story begins in 1998 with the
patent of Sabsabi and Bussie`re that describes a spectroscopic
method and apparatus for pharmaceutical analysis.23 Soon after,
a wide range of pharmaceutical applications for LIBS began to
emerge.24–32 These applications include the monitoring of the
active pharmaceutical ingredients (API) and a formulation
lubricant such magnesium stearate29 as well as the possibility
of generating the first results capable of globally mapping phar-
maceutical solid dosage forms.26As is typical in NIR and Raman
reflectance spectroscopy, pure components are analysed before
their preparation in a solid dosage form. Although, for these
baseline spectral techniques, it has been shown that physical
properties, such as particle size, will result in spectral diffusion
that limits the applicability of these baseline spectra to facilitate
the differentiation of physical changes from chemical or compo-
sitional changes that may result from the combination of these
components into a formulation.33–35 Additionally, matrix effects
and excipient interactions may limit the use of these reflectance
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baseline spectra and affect overall spectral information.33–35With
molecular LIBS spectroscopic analysis we have shown good
selectivity for those pharmaceutical formulation constituents
without the need of baseline spectra.30 Well established reflective
spectroscopic techniques such as NIR and Raman are also
hindered by the penetration depth at the solid dosage form
surface.36–38 Whereas LIBS has the distinct ability to selectively
obtain information at the tablet surface and throughout the
entire tablet without spectral diffusion that is usual with NIR
and Raman transmission techniques.
Another important application of LIBS for pharmaceutical
materials is the analysis of coating thickness and uniformity on
the tablet26 for rapid at-line analysis for enhanced process
control. LIBS has also been applied to the on-line monitoring
of liquid pharmaceutical formulations,28 which have demon-
strated the on-line/in-line process monitoring capability of
LIBS. It is only as recently as 2006 that LIBS applications for
pharmaceutical materials were first reviewed in a book chapter.25
The technique has also been compared to traditional analytical
techniques, such as scanning electron microscope coupled with
energy dispersive X-ray emission (SEM-EDX)31 and with near-
infrared (NIR) spectroscopy, for determination of magnesium
stearate, a critical formulation ingredient necessary for ensuring
product performance.32 The efforts of these early LIBS
researchers have highlighted the presence of the ‘‘matrix effect’’.
To overcome the matrix effect resulting primarily from physical
property variations induced by the manufacturing changes on
solid dosage forms, efforts have been made to understand the
influence of many parameters on the LIBS signals.24,27,39
These atomic LIBS studies agree that the use of matrix-matched
calibration standards are necessary to overcome the matrix
effect to produce accurate quantitative results.24,27,39,40 Since
atomic LIBS signals can be affected by many physical parameters
in the manufacturing process, traditionally known as matrix-
effects, two research studies24,27 have demonstrated that the
LIBS technology is a valuable tool for process analytical
technologies. The matrix effect is sensitive enough to be utilized
for an in-process monitoring approach for pharmaceutical
manufacturing.39,40
The basic hypothesis of the molecular LIBS approach devel-
oped here is that the emission from small molecular fragments
coming from the laser-induced plasma are characteristic of the
parent molecules fragmented in the creation of the latter. It is
well known that the fragmentation of a molecule is a function
of the chemical bonding and the functional groups present in
the molecule. The fundamental molecular structure, the nature
of the bonds, the conformation, and the isomers contribute to
the specific nature of the molecular emission. We propose to
use the emission signal from the small molecular fragments
coupled with chemometrics to evaluate the primary chemical
structures in pharmaceutical formulations. Using favorable
experimental conditions, the fragmentation will produce selec-
tive daughter molecular fragments from the primary or parent
molecule. Molecular bands emission will be used, for the first
time to the best of our knowledge, for the determination of the
chemical moieties and the evaluation of the chemical structure
of both the API and excipients in a complex pharmaceutical
formulation. Molecular LIBS is an information rich multiplex
spectral technique which contains both atomic and molecular
emission spectra that, following analysis by multivariate
approaches (i.e. chemometrics), will extract this unique combina-
tion (molecular, atomic, ionic) of spectral information from
molecular LIBS. Additionally, molecular LIBS is able to avoid
many of the classical spectroscopic limitations such as light
scattering, diffusion, absorption, penetration depth, sample
preparation, material type, etc. These inherent advantages
provide a broader range of problem solving capability (e.g. accu-
rate depth profiling, 3D chemical mapping, direct solid, liquid
and gas analysis) and can be used for in-process control (raw
materials), process control (blending, mixing, tableting), process
understanding, process analytical technology (PAT), quality by
design (QbD), risk management and quality assurance.
Although this work focuses primarily on pharmaceutical appli-
cations, the potential for molecular LIBS transcends pharmaceu-
ticals and extends analytical science, opening the door to many
useful applications.
This study investigated the laser-induced molecular bands
emission coupled with chemometrics for the qualitative and
quantitative analysis of molecular compounds found in a model
pharmaceutical formulation. Our goal is to establish laser-
induced plasma conditions that enhance selective emission of
molecular fragments from the sample. By doing so, we can
analyze the photons emitted by small diatomic fragments with
a conventional optical spectrometer that will be mathematically
processed with chemometrics to study the parent compounds,
such as API and excipients, simultaneously. To the best of our
knowledge, this spectroscopic approach is the first documented
effort to conduct qualitative and quantitative analysis of both
API and excipients simultaneously using laser-induced break-
down spectroscopy or with any other atomic emission spectros-
copy based techniques.
Experimental
Apparatus and materials
A Nd:YAG laser operating at 1064 nm (Surelite II-10,
Continuum, Santa Clara, CA, USA) producing pulses of 6 ns
duration (full width at half maximum) was used. The pulse
energy at the laser exit was 100 mJ. The laser beam was focused
on the tablet surface using a plano-convex lens (515 mm focal
length), producing crater diameters of approximately 500 mm.
The horizontal beam was incident on the vertical tablet surface
at 90 as represented in Scheme 1.
The tablet was held in a custom-made sample holder which
could accommodate 12 mm tablet. The sample holder was
mounted on a motorized X–Y stage, allowing programmable
analysis at several sites on a given tablet. The experiments
were performed in argon at atmospheric pressure using a
1 L min1 argon flow on the target. The light given off by the
laser-induced plasma was collected head-on by a mirror and
then directed to a 0.66-m Czerny-Turner spectrometer
(McPherson, Acton, MA, USA). Using a lens, the plasma was
imaged with 1 : 2 magnification on the entrance slit of the
spectrometer, which is equipped with a 150 grooves per mm
grating blaze at 500 nm. The dispersed light was detected at
the exit slit of the spectrograph with an intensified photo-diode
array (IPDA) (Princeton Instruments, Trenton, NJ, USA)
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detector. The emission signal was time-resolved using a pulse
generator (Princeton Instruments, model PG-200) (itself
synchronized with the laser pulse) by sending a gating
signal to the intensifier with a delay of 4 ms and a pulse width
of 750 ns, these conditions were found to be optimal regarding
the signal to noise ratio and repeatability of the analytical
signals.
The pulse repetition rate was 2 Hz, allowing 99 measurements
on a given tablet to provide a representative average
compositional analysis in less than 50 seconds for the 3 3 raster
(i.e. 9 sampling sites  11 shots per site ¼ 99 laser shots per
sample). Each laser shot produced 726 pixel intensities that
were averaged (n ¼ 90) for each sample without the first shot
at each site (n ¼ 9), to avoid any potential surface contamina-
tion. Therefore, a sample spectra composed of 726 mean
pixel intensities resulting from 90 laser shots per sample was
stored for each analyzed standard. The dependent variable
matrix for the calibration set was composed of 90 spectra
(i.e. 15 standards  6 replicates, formulation A to O, Table 1)
and 18 spectra (i.e. 3 standards  6 replicates, formulation
P to R, Table 1) for the validation set. The corresponding inde-
pendent variable matrix was built from the data presented in
column 4 to 7 from Table 1 (e.g. for the calibration set: 90 stan-
dards  4 components). Thereafter, this matrix of data was
introduce into PLS or PCR models and pre-processed if neces-
sary as specified in the text.
The experimental set-up and spectral data were controlled
using a custom application developed in LabVIEW 6 (National
Instruments, Austin, TX, USA). Spectral data post-treatment
with chemometrics was performed using a custom algorithm
under Matlab 7.5 environment (The MathWorks Inc., Natick,
MA, USA). The Matlab built-in singular value decomposition
(SVD) function was used in order to extract the principal
components used for the construction of principal component
regression (PCR). For the construction of partial least square
(PLS) regression a PLS2 model was used.41
Calibration standards
For each standard, 6 replicate tablets were prepared. The powder
mixing was done by mortar and pestle mixing for 5 minutes using
the formulation quantities presented in Table 1. The solid dosage
form tablets were prepared by compressing 320 mg of powder
with 2000 psi (Enerpac, P112, Whaley Bridge, High Peak, UK)
for 15 s. The furosemide API used in the model formulation
was Lot 36 H0944 (Sigma-Aldrich, St-Louis, MO, USA). Avicel
PH 101 (Lot 6108C), (FMC BioPolymer, Philadelphia, PA,
USA) was used with lactose 200 M monohydrate (Lot
M00448), (Mallinckrodt, St. Louis, MO, USA) as excipients.
Magnesium stearate (Lot M00295, Mallinckrodt) was used in
the formulation as lubricant.
Safety considerations
It is important to note that there are some safety considerations
and the reader is invited to consult ref. 42–44 for more
information.
Scheme 1 Simplified representation of the experimental set-up.
Table 1 Composition of the model formulation
Standard name Lactose in matrix (%) Furosemide (% of nominal) Furosemide/mg Lactose/mg Avicel/mg Mg Stearate/mg
A 0 80 64 0 255.2 0.8
B 0 100 80 0 239.2 0.8
C 0 120 96 0 223.2 0.8
D 50 80 64 127.6 127.6 0.8
E 50 100 80 119.6 119.6 0.8
F 50 120 96 111.6 111.6 0.8
G 100 80 64 255.2 0 0.8
H 100 100 80 239.2 0 0.8
I 100 120 96 223.2 0 0.8
J 0 80 64 0 253.2 2.8
K 50 100 80 118.6 118.6 2.8
L 100 120 96 221.2 0 2.8
M 0 80 64 0 249.6 6.4
N 50 100 80 116.8 116.8 6.4
O 100 120 96 217.6 0 6.4
Pa 25 90 72 61.75 185.25 1
Qa 75 110 88 171 57 4
Ra 40 85 68 100 150 2
a Standard used as validation standard.
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Results and discussion
Selectivity of the laser-induced plasma
The chemical structures of the molecules studied with the model
formulation are presented in Scheme 2. It should be quickly
noted that the furosemide molecular structure is the only one
that contains target sulfur, nitrogen and chlorine atoms when
compared to the other molecular structures of the excipients
present in the model formulation, such as magnesium stearate,
Avicel and lactose.
The traditional approach for the analysis of the active phar-
maceutical ingredient (API) was to monitor the emission signal
of a target element.29 Therefore, the peak height or peak area
of the signal resulting from sulfur or chlorine atomic lines, in
the case of furosemide, can be plotted against the concentration
to produce a calibration curve for quantification of furosemide.
The advantage of such an univariate approach is that it uses
simple mathematics for calibration and therefore a quantitation
approach that is generally well understood by the analyst in the
laboratory. However, this approach requires matrix-matched
calibration standards to produce an accurate prediction.24,27
Following the set-up of a favorable argon atmosphere that will
minimize the contribution of air to the laser-induced plasma and
at the same time enhance the molecular band emission signal, we
performed the molecular LIBS spectroscopic experiments on
a series of model formulations composed of furosemide, Avicel,
lactose and magnesium stearate. Avicel and lactose are pharma-
ceutical excipients (inactive pharmaceutical ingredients) that
represent typically 80 percent of the total mass of a pharmaceu-
tical solid dosage form. In analytical chemistry, these excipients
are named the matrix since they are the major constituents of the
sample other than the analytes. Characteristic spectra produced
from a laser-induced plasma from a furosemide pharmaceutical
formulation is presented in Fig. 1. It is important to note that
these characteristic spectra are highly reproducible (RSD% for
the spectra varies between 0.45 to 2.7% depending on the camera
pixels for 6 standard replicates) with low resolution (resolving
power l/Dl  700 based on 3 pixels) that provides the required
selectivity for building the chemometric models. The perfor-
mance of this approach is comparable to traditional molecular
spectroscopic procedures.
The spectra presented in Fig. 1 show the emission of many
small diatomic fragments such as CN, CH and C2 for a constant
matrix composed of pure lactose as the excipient. Furthermore,
it is also possible to observe the presence of atomic lines of
carbon, hydrogen and magnesium and two ionic lines of calcium.
The laser-induced spectra presented in Fig. 1 shows the LIBS
response for 80, 100 and 120% of the label claim for furosemide
while the other excipients remain constant with 100% lactose. It
is possible to observe that the tree series of molecular bands of C2
(roughly between 455–475 nm, 500–520 nm and 540–565 nm)
vary with the increase of the API concentration. The emission
of the C2 bands is in agreement with previous univariate work
which associates the C2 emission with the presence of the unsatu-
ration in the molecule.30 On the other hand, the two ionic lines of
calcium at 393 and 397 nm in Fig. 1 remain constant. The other
molecular bands of CN and CH in addition with the atomic lines
of H and C in Fig. 1 are less affected by the increase of the API
concentration. These spectral behaviors indicate a correlation
between variables for which chemometric models are presently
uniquely capable of processing; which clearly demonstrate the
information rich nature of molecular LIBS spectra.
The CN molecular bands emission is a result of the furosemide
fragmentation and the recombination between C and N atom in
the plasma. Since, the experiments were conducted under argon
atmosphere, the CN emission from the recombination of these
atomic species present in the plasma should not come from the
recombination between C2 in the plasma and N2 from the air.
St Onge et al. have demonstrated the kinetic evidence of this
recombination reaction in air to produce CN.30 Therefore, the
CN emission signal is a result of the elemental and molecular
nature of the plasma. Hence, the CN emission can be primarily
attributed to the presence of furosemide molecules. Nitrogen is
present in furosemide, but it is not present in lactose, cellulose,
or magnesium stearate. Consequently, the CN emission can be
primarily attributed to the presence of furosemide in the ablated
sample. If we theoretically infer, as suggested by Acquaviva, that
the CN emission origin was a result from some other nitrogen
contamination from the air (N2 air or adsorb).
45 Then, following
this reaction:30
Scheme 2 Chemical structures of the different molecular compounds
present in the model furosemide formulations.
Fig. 1 Molecular LIBS spectra obtained for different active pharmaceu-
tical ingredient concentrations in the furosemide formulation (lots G, H
and I).
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C2 plasma + N2 air or adsorb/ 2 CNplasma (1)
it can be reasonably inferred that this spectral contribution won’t
be correlated to the presence of furosemide. Therefore, the
multiplex signal generated by the mixed matrix standards
accurately describes the furosemide in the formulation. In
addition, this CN contribution (eqn (1)) to the LIBS spectra
will be relatively constant with a small random variation. It
will not significantly impact the accurate quantitative analysis
of the furosemide molecules. Therefore, multivariate regression
models such PLS and PCR would not capture this part of the
spectra, leaving it in the residual with the noise and the
uncorrelated spectral variations.41
We present in Fig. 2 the mean emission spectra obtained for 6
replicate spectra of our model pharmaceutical formulations
containing 3 different Avicel/lactose ratios while maintaining
the API (at 100% of the nominal content in furosemide) and
lubricant concentration constant. It is possible to observe that
the molecular bands present between 390 to 520 nm are sensitive
to changes in the matrix composition. The two calcium ionic
emission lines observed as the net intensity at 393 and 397 nm
are inversely proportional to the Avicel content. This indicates
that lactose contains more calcium than the Avicel which seems
obvious since lactose is generally extracted from milk. Interest-
ingly, the presence of Avicel seems to contribute globally to
the emission bands and atomic lines in this spectroscopic
window. In fact, the presence of Avicel impacts the entire
spectrum presented in Fig. 2 in the same spectroscopic pattern
as lactose. The latter observation can be quite obvious when
considering the characteristics of the molecular structures of
Avicel and lactose presented in Scheme 2. The chemical
building block of Avicel (cellulose) is nearly identical to the
structure of lactose, the differences consist of two fewer
hydrogen, and that Avicel is a polymer containing between
500 and 5000 units whereas lactose is a dimer. On the other
hand, this does not explain the significant signal intensity differ-
ence observed for these two materials. A reasonable explanation
for this phenomenon may be that since Avicel is a polymer, the
fragmentation might be less effective, producing more molecular
fragments. In other words, the fragmentation for lactose leads to
the greater production of atoms and ions and less molecular
fragments than in the case of Avicel.
Construction of chemometrics model
The molecular LIBS spectroscopic data presented in Fig. 1 and
Fig. 2 highlight the physico-chemical properties and the
statistical requirements required for the building of a reliable
chemometrics model as recommended by Gemperline.41 The
molecular LIBS emission spectra obtained for the calibration
set and the validation set are presented in Fig. 3.
It is possible to observe each distinct individual mean
spectrum (n ¼ 6) in Fig. 3 which reveals the selectivity of the
molecular LIBS emission spectra for the different standards
using this spectral window. The individual spectra were used
for constructing the chemometric calibration (formulation A to
O) and validation (formulation P to R) sets. The evaluation of
various data pre-treatments (i.e. raw data, mean-centering, range
scaling and auto-scaling) for principal component regression
(PCR) and partial least square (PLS) is presented in Table 2.
This table reports the corresponding root mean square error of
calibration (RMSEC), the root mean square error of prediction
Fig. 2 Molecular LIBS spectra obtained for different major excipients
composition in the furosemide (nominal 100%, lots B, E and H).
Fig. 3 Mean molecular LIBS spectra obtained for the calibration and
validation standard sets average spectra (n ¼ 6) for the model
formulations presented in Table 1. The individual spectra were used
for constructing the chemometric calibration and validation sets.
Table 2 Evaluation of PCR and PLS for different data pre-treatments
Data pre-treatment nLVa
Furosemide
RMSECb/mg
Furosemide
RMSEPc/mg R2d
PCR
Raw data 10 6.36 6.64 0.956
Mean centering 9 7.32 5.98 0.935
Range scaling 8 6.56 6.71 0.954
Auto-scaling 7 5.99 6.88 0.959
PLS
Raw data 5 11.0 5.94 0.952
Mean centering 5 5.93 9.99 0.929
Range scaling 5 7.30 5.88 0.957
Auto-scaling 5 7.18 5.54 0.964
a Number of latent variables considered in the model. b Root mean
square error of calibration. c Root mean square error of prediction.
d R-square calculated on the calibration set.
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(RMSEP) for furosemide, and correlation coefficient (R2)
obtained for the different possibilities.
It is observed in Table 2 that the best combination based on
our conditions is PLS coupled with auto-scaling. This combina-
tion presents the least number of latent variables with the lowest
RMSEC and RMSEP (i.e. prediction errors) for furosemide. It
should be noted that the same data pre-treatments also mini-
mized the errors for the other constituents (data not shown).
The determination of an optimal number of latent variables is
considered fundamentally essential for PCR or PLS, and can be
evaluated by examining the plot of the RMSEC and RMSEP
against the number of latent variables, shown in Fig. 4 for the
PLS model with auto-scaling. It is then possible to observe
that the calibration error (RMSEC) and the prediction error
(RMSEP) drops significantly after four latent variables which
is consistent with the number of compounds in our formulation
(i.e. four). The RMSEP, which corresponds to prediction error
of the validation set, passes through a minimum at five latent
variables before it rises again, as is often observed when building
PLS or PCR models. It is important to note that additional
latent variables will start to include non-significant variation in
the spectra, which will then increase the prediction error (i.e.
RMSEP) since the regression model will start to model random
noise and other non-correlated spectral data; this is typically
referred to as over fitting in chemometrics terms.
In theory, the number of latent variables expected should be
the same as the number of independent variables, which is four
in this case (i.e. furosemide, Avicel, lactose and magnesium
stearate). However, in practice, it is often a few more than
what the theory suggests, such that non-linear behavior of the
signal and uncontrolled parameters in the calibration set can
require additional latent variables to build a PCR or PLS model.
Since manufacturing changes influence the LIBS signal, it should
be possible to identify some ‘‘buried’’ variables using a more
complex calibration set using a design of experiment (DOE)
approach with an additional independent variable such as
manufacturing changes (e.g. compression strength). The fact
that the number of latent variables is five compared to four
independent variables is a good indication of the validity of
the developed PLS model with auto-scaling. Researchers from
other spectroscopic fields have shown that near-infrared
spectroscopy is influenced by the compression strength.46 Hence,
this could also be the case with molecular LIBS; consequently,
this additional latent variable can be attributed to the compres-
sion strength. Present work on molecular LIBS shows that the
compression strength is a significant independent variable that
influences molecular LIBS signals.
Validation of the PLS model for five latent variables is
presented in Fig. 5 for the comparison of the predicted mass in
the formulation against the weighted mass for the prepared
standard. The 1 : 1 correspondence line shows the precise agree-
ment between the predicted values and the weighted mass. For
the calibration set, the predicted values are in good agreement
with the weighted mass for the calibration standards, the R2
corresponding to all formulation ingredients for the calibration
set is good with a noted value of 0.964. The worst cases are
observed for the prediction of Avicel and lactose (red and green
points in Fig. 5), where bias between the predicted values and the
weighted mass in formulation is less than 15% relative. Overall,
these results are a breakthrough considering that the pharmaceu-
tical manufacturers do not possess a process analytical sensor
technology that enable the fast monitoring of excipients like
Avicel and lactose. For the other pharmaceutical ingredients,
furosemide and magnesium stearate (blue and cyan points in
Fig. 5), the relative accuracy for the prediction of the validation
standards, expressed in percent is less than 4%. This is an excel-
lent result showing that it is possible to predict accurately an API
without the use or requirement of a traditional tag element in
atomic LIBS. Collectively the statistics for RMSEC and RMSEP
are shown in Table 3.
Nevertheless, the standard prediction for lactose and Avicel
reveals more scatter than for the API and lubricant compared
to the weighted mass in the formulation. Considering the fact
that the standards prepared in this study were made manually
using mortar and pestle, weighting and non-automated
compression methods, all these physical manipulations might
incorporate additional random variations in the data sets. It
may also indicate that several physical parameters may influence
Fig. 4 Plot of the root mean square error of calibration and prediction,
respectively, for the calibration and the validation set as a function of the
number of latent variable considered in the partial least square model.
Fig. 5 Comparison between the predicted mass and the weighted mass
for the different compounds entering in the studied furosemide formula-
tion for the calibration set and the validation set for the PLS model using
five latent variables. Points represent the mean of the six standard
replicates and error bars represent the corresponding standard error.
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the LIBS signal, as previously shown by other studies.24,27 This
places a greater importance on the use of standard calibration
sets prepared under current good manufacturing practices
(cGMP) conditions. The latter may have shown less spectral
bias. Alternative studies in our laboratory using cGMP prepared
formulation sample sets have provided preliminary data that
seem to support this hypothesis. Future work will utilize
cGMP sample sets for pharmaceutical studies which will require
extensive validation and robustness testing to verify this hypoth-
esis. Furthermore, the new calibration set should consider the
potential manufacturing changes that may influence the molec-
ular LIBS signals using a DOE approach that will spread the
variance of these independent variables.
Preliminary pharmaceutical applications with atomic LIBS
focused on the determination of the API or excipients in drug
formulations with tag elements. Typically, it was difficult to
accurately determine the API without matrix-matched standards
due to the matrix effect. The analytical requirement for standard
preparation offsets LIBS intrinsic analytical advantages of
efficient direct determinations without sample preparation.
Additionally, the direct determination of major excipients such
as Avicel, lactose, etc. was not readily accessible through
traditional atomic spectroscopy techniques that were limited by
sensitivity and selectivity issues. These spectroscopic and sensi-
tivity limitations mostly confined LIBS to laboratory based
confirmatory measurements, generally in a research setting.
Applications such as the 3D-chemical mapping or accurate
determination of coating thickness could provide important in
vitro quality control tools to better assess in vivo drug bioavail-
ability by predicting and or verifying drug dissolution. Our
results indicate that it is now fully feasible to implement LIBS
as an on-line or near-line PAT setting for in-process monitoring
of manufacturing unit operations such as mixing or blending or
even in process control. With the development of molecular
LIBS and the potential for the simultaneous determination of
API and excipients in complex matrices, the potential pharma-
ceutical applications should increase dramatically. Currently,
no other PAT sensor technology or analytical technique can
duplicate the broad applicability of this methodology. This
suggests that molecular LIBS can actively monitor and provide
efficient data for real time process monitoring over a wide range
of manufacturing operations. Molecular LIBS could comple-
ment existing PAT sensor technologies such as near-infrared
spectroscopy, chemical imaging and Raman spectroscopy.
When coupled with standoff capability, molecular LIBS has
the potential to dramatically enhance analytical capabilities in
a PAT environment and evolve process understanding to
a currently unimagined level, with efficient real time global
(surface and interior) analysis of drug blends and final solid
dosage forms.
Molecular LIBS may also provide a powerful pharmaceutical
research tool that can enhance excipient screening, formulation
development through novel dosage form assessment of
excipient–API interactions, migration, tablet preparation, and
ultimately formulation understanding that will provide a novel
in vitro approach to in vivo performance.
Conclusions
We have demonstrated that LIBS coupled with chemometrics
can provide the complete and simultaneous qualitative and
quantitative prediction of all ingredients present in a pharmaceu-
tical formulation. Molecular LIBS possess the capability to
produce a combination of selective molecular, atomic and ionic
emission signals that can differentiate between various molecules
composing a complex matrix such as a pharmaceutical
formulation.
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